CTOs on the Move

Terns Pharmaceuticals

www.ternspharma.com

 
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns` programs are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients. Terns` investors include OrbiMed, Vivo Capital, Lilly Asia Ventures, and Decheng Capital.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ternspharma.com
  • 1065 East Hillsdale Boulevard Suite 100
    Foster City, CA USA 94404
  • Phone: 650.275.4395

Executives

Name Title Contact Details

Funding

Terns Pharmaceuticals raised $30M on 04/03/2018
Terns Pharmaceuticals raised $80M on 10/30/2018
Terns Pharmaceuticals raised $87M on 01/05/2021

Similar Companies

Auxillium East

Auxillium East is a Wayne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Indicus Pharma

Indicus Pharma is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients` needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

BioXcel Therapeutics

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company`s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company`s two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.

Medical Components

Dialysis and Vascular Access Products